MedWatch

Novo cancels development of hemophilia drug

Novo Nordisk has decided to cancel the development of a drug against hemophilia after patients formed anti-drug antibodies in studies with the medicine.

Foto: Colourbox

Novo Nordisk announces that it is shelving the development of the drug vatreptacog alfa for hemophilia patients with inhibitors. The drug was being tested in phase III studies.

After analyzing phase IIIA results from August the pharmaceutical group discovered that “a few patients had developed antibodies against vatreptacog alfa”, and the company is quick to react.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier